The Spark is a Lantern Pharma newsletter that provides succinct and frequent updates about Lantern, our RADR® AI and ML platform, and our pipeline of drug programs. Subscribe to the newsletter to receive it by email or see the most recent editions below.
The March 2023 edition of The Spark features the latest company updates including:
Lantern activated its fifth Harmonic™ clinical trial site in Los Alamitos, CA at the Cancer and Blood Specialty Clinic. Across its five sites, Harmonic™ has 12 different locations across the US, with multiple additional sites expected to be activated in Q2 2023.
Across the 5 Harmonic™ clinical trial sites, there is 1 consented patient that is anticipated to be dosed in Q1/Q2 2023 and 14 additional potential patients that have been pre-screened and are being monitored for possible enrollment.
What's next: All five clinical trial sites, Gabrail Cancer Center, Northwest Oncology, New York Cancer and Blood Specialists, Texas Oncology, and Cancer and Blood Specialty Clinic, are in the process of screening patients and are targeting to enroll the first patients in Q1/Q2 2023.
Go deeper: For more information on the Harmonic™ clinical check out the:
The investigational new drug (IND) enabling studies for LP-184 have been completed and the submission of the IND application to the US Food and Drug Administration (FDA) is anticipated in April 2023.
What's next: The upcoming LP-184 Phase 1A basket trial is expected to launch in Q2 2023 and enroll 30-35 patients with solid tumors and central nervous system (CNS) cancers including:
Go deeper: Below is the planned Phase 1A clinical trial design for LP-184.
By the numbers: Globally, the combined annual market potential of these programs is estimated to be approximately $11.0-13.0 billion, consisting of $5.0-6.0 billion for CNS cancers and $6.0-7.0 billion for solid tumors.
Starlight Therapeutics is a wholly-owned Lantern subsidiary that was formed to develop drug candidate LP-184’s central nervous system (CNS) and brain cancer indications – including glioblastoma
(GBM), brain metastases (brain mets.), and several rare pediatric CNS cancers. Starlight will refer to the molecule LP-184, as it is developed in CNS indications, as “STAR-001”.
Go deeper: STAR-001 has demonstrated blood-brain barrier permeability, has favorable brain tumor bioavailability, and has shown nanomolar potency across an extensive number of in-vitro and in-vivo CNS and brain cancer models.
What’s next: In mid-2023, Lantern is anticipating a Phase 1A basket trial for LP-184/STAR-001 (see above), in a range of solid tumors including: recurrent brain cancers (including GBM and HGGs), metastatic CNS cancers (brain mets.), pancreatic cancer, and solid tumors with DDR deficiencies. The clinical development of STAR-001 in CNS cancers beyond the Phase 1A trial will be conducted exclusively by Starlight.
By the numbers: Combined, STAR-001’s targeted treatment indications are estimated to represent an annual global market potential of approximately $5.0-6.0 billion and over 500,000 global cases each year.
Lantern and TTC Oncology recently established an AI-driven collaboration leveraging Lantern’s AI platform RADR® to enhance the development of TTC’s Phase 2 ready drug candidate, TTC-352.
TTC-352 is a novel, first- and best-in-class, selective human estrogen receptor (ER) partial agonist (ShERPA) for the treatment of patients with metastatic ER+ breast cancer.
Go deeper: The initial aims of the collaboration will be to:
By the numbers: ER+ breast cancers are estimated to account for 75-80% of all breast cancer cases and can have a recurrence rate between 13% and 41%. Globally, the treatment of ER+ breast cancer is estimated to have a $44 billion market potential by 2027.
Lantern is expanding RADR®’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of potent anti-cancer small molecules to cancer cells.
Highlights of RADR®’s product roadmap for ADCs:
By the numbers: Globally, ADC drug programs are one of the fastest growing drug development markets. In 2021, the ADC market was over$4.o billion and is projected to represent a global market potential of over$14 billion by 2027.
This month we hosted a key opinion leader (KOL) webinar on synthetic lethality the powerful mechanism of action behind Lantern’s drug candidates LP-184, LP-284, and LP-100. The webinar features a leading expert on synthetic lethality in DNA damage response (DDR) deficient cancers Zoltan Szallasi, M.D.
During the webinar, Dr. Szallasi discussed a broad range of topics including:
Link to replay of the KOL Webinar on Synthetic Lethality:
What’s next: In Q2, we will host Part 2 of our Synthetic Lethality KOL webinar series with Lantern’s very own Chief Scientific Officer, Kishor Bhatia, Ph.D. Additional information on the webinar will be announced in the coming weeks.
Links to Q4 & full year 2022 earnings call replay and press release:
This newsletter contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events, our plans to advance the development of our drug candidates and antibody drug conjugate program, or our future financial performance. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the impact of the COVID-19 pandemic, (ii) the risk that our research and the research of our collaborators may not be successful, (iii) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (iv) the risk that no drug product based on our proprietary RADR® A.I. platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (v) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 10, 2022. You may access our Annual Report on Form 10-K for the year ended December 31, 2021 under the investor SEC filings tab of our website at www.lanternpharma.com or on the SEC's website at www.sec.gov. Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this newsletter represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.